Press Releases
Media Alert: successful registration after shortest ever review by the FDA of Eloxatin
Dyax Corp. and Debiopharm S.A. report successful results of phase IIA clinical trial with DX-890 for cystic fibrosis
Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland
H3 Pharma announces promising developments for the treatment of Alzheimer´s disease
Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury
Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004
H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…
Swiss company Debio R.P. announces Agreement with Inhale subsidiary Shearwater Corporation